All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
Filing 2024 Q3 - Restatement compared to 2024 Q2 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Oguzhan Demirel
Member of Management
Zurich, Switzerland
11/13/2024
This Form 13F-HR/A ("Amendment") is a restatement of the Form 13F-HR filed on November 8, 2024 for the calendar quarter ended September 30, 2024 (the "Original Filing"). This Amendment supersedes the Original Filing and is being filed to correct a specific inaccuracy in the reporting of the number of shares of an issuer (ONCONETIX INC) held by the filer.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.